In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines

BACKGROUND: Cholangiocarcinoma (CCA) is a slowly progressing but highly aggressive malignancy. Targeting the HER protein family represents a potential therapeutic strategy for CCA treatment. The pan-HER inhibitor varlitinib is being developed for the treatment of breast cancer, gastric cancer, and b...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Drug Des Devel Ther
Glavni autori: Dokduang, Hasaya, Jamnongkarn, Wassana, Promraksa, Bundit, Suksawat, Manida, Padthaisong, Sureerat, Thanee, Malinee, Phetcharaburanin, Jutarop, Namwat, Nisana, Sangkhamanon, Sakkarn, Titapun, Attapol, Khuntikeo, Narong, Klanrit, Poramate, Loilome, Watcharin
Format: Artigo
Jezik:Inglês
Izdano: Dove 2020
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7296552/
https://ncbi.nlm.nih.gov/pubmed/32606601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S250061
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items